Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV1 Broadly Neutralizing Antibodies
ID: NIH/NIAID 124Type: BOTH
Overview

Topic

Development of Next-Generation Devices and Materials-Based Platforms for the Administration of HIV1 Broadly Neutralizing Antibodies

Agency

Department of Health and Human ServicesNational Institutes of Health

Program

Type: SBIRPhase: BOTHYear: 2023

Topic Link

https://www.sbir.gov/node/2451725

Additional Information

https://sam.gov/opp/aa72581c848947f0b61c15062e604862/view
Timeline
  1. 1
    Release Aug 25, 2023 12:00 AM
  2. 2
    Open Aug 25, 2023 12:00 AM
  3. 3
    Next Submission Due Nov 14, 2023 12:00 AM
  4. 4
    Close Nov 14, 2023 12:00 AM
Description

The National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) are seeking proposals for the development of next-generation devices and materials-based platforms for the administration of HIV1 broadly neutralizing antibodies. The goal is to improve the delivery of these antibodies for HIV prevention or other indications. The research aims to enhance potency, increase tissue levels, extend half-life, and target multiple sites of vulnerability on the HIV Envelope glycoprotein. The project duration for Phase I is up to 1 year with a budget of $300,000, while Phase II has a duration of up to 3 years with a budget of $2 million. The solicitation is closed, and 1-3 awards are anticipated. The research may involve the development of dermal patches, controlled-release hydrogels, nanoparticle carriers, vaginal rings, implantable devices, and nucleic acid delivery systems. The expected impacts include increased end-user acceptability, improved adherence, reduced administration-associated cost and time, and improved efficacy by maintaining sustained antibody titers. For more information, refer to the solicitation notice on grants.gov.

Files
No associated files provided.
Similar Opportunities
NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required). This solicitation encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to implement investigator-initiated clinical trials, including mechanistic studies associated with clinical trials. The program supports milestone-driven, hypothesis-driven clinical trials related to the research mission of the NIAID that address high-priority research areas. The solicitation encourages high-risk clinical studies, which involve non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged. The funding supports the conduct, completion, and analysis of a single clinical trial, including activities such as training of study personnel, enrollment and recruitment of study subjects, data collection and management, laboratory work, safety monitoring, and regulatory activities. The project duration is not specified, but the application due dates are provided. More information can be found on the grants.gov website.
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of novel tools and devices for animal research facilities and to support the care of animal models. The Office of Research Infrastructure Programs (ORIP) is encouraging applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects in this area. The goal of this solicitation is to improve animal welfare, ease the management of individual animals and animal colonies, and enhance the monitoring and control of environmental conditions that affect outcomes and reproducibility in animal model research. The variation of extrinsic factors between different animal facilities has been cited as a source of irreproducibility in animal research, and this solicitation aims to address this issue. The solicitation specifically calls for the development and implementation of novel tools and devices to monitor environmental conditions, identify pathogens and contaminants, and enable noninvasive or minimally invasive monitoring of animal behavior and bodily functions. The devices should be discreet, robust, easy to apply, and mobile. Additionally, the solicitation seeks new software that can combine data from different monitoring devices and be compatible with different data formats. The solicitation emphasizes the importance of innovation and encourages the adaptation of technologies from other fields to improve animal research. It applies to a broad range of animal models, including invertebrate and vertebrate animals, and excludes disease-specific devices, reagents, and experimental protocols. Examples of specific tools and devices that can be developed include portable software for managing and evaluating animal colonies, noninvasive tracking and monitoring technology, automated feeding systems, devices for drug delivery and measurement, improved systems for data collection and analysis, better phenotyping devices, improved holding and transfer devices, and enhanced air and water filters for animal facilities. The solicitation is open for applications until September 6, 2024, and applicants are advised to discuss their projects with the Scientific/Research contacts before submitting an application. More information can be found on the grants.gov website.
HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of therapies and technologies directed at enhanced pain management through the Small Business Innovation Research (SBIR) program. The focus of this solicitation is on improving pain measurement and treatment. The goal is to address the national opioid public health crisis by providing scientific solutions for chronic pain, which affects over 25 million Americans. The research objectives include enhancing pain management through the development of new screening tools, models, and therapies, as well as advancing non-addictive pain analgesic treatments and improving pain management strategies for acute and chronic pain conditions. The solicitation is open for applications until April 5, 2025, and interested applicants can find more information on the grants.gov website.
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. The focus of this solicitation is on improving pain measurement and treatment. The goal is to address the national opioid public health crisis by providing alternative treatment options for chronic pain, which affects over 25 million Americans. The research objectives include the development of tools and technologies to understand the biological underpinnings of chronic pain, the discovery and pre-clinical development of non-addictive analgesic treatments, and the advancement of new pain treatments through the clinical pipeline. The solicitation is open to various fields, including biology, medicine, engineering, and technology. The project duration can vary, and the funding specifics can be found on the grants.gov website. The open date for submissions is December 4, 2022, and the close date is April 5, 2025. For more information and to access the solicitation, visit the provided links.
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
Active
Department of Health and Human Services
The Department of Health and Human Services, specifically the National Institutes of Health, is seeking proposals for the development of regulated therapeutic and diagnostic solutions for patients affected by opioid and/or stimulant use disorders (OUD/StUD). The current drug crisis surrounding these disorders has resulted in a significant number of deaths and an urgent need for comprehensive solutions. The solicitation is focused on the research and development of medical products regulated by the U.S. Food and Drug Administration (FDA), including pharmacotherapeutics and medical therapeutic and diagnostic devices. In the area of pharmacotherapeutics, the solicitation encourages the development of small or large molecule agents, biologics, natural products, longer-acting formulations of existing addiction medications, advanced drug delivery systems, and the development and characterization of biomarkers. Proposed activities may include target identification, assay development, lead optimization, preclinical studies, formulation development, and process development. The ultimate goal is to file an Investigational New Drug (IND) application and conduct clinical studies to support the filing of a New Drug Application (NDA) or a Biological License Application (BLA). In the area of medical therapeutic and diagnostic devices, the solicitation seeks research and development of imaging technologies, devices for diagnosing and reducing craving and withdrawal symptoms, therapeutic devices, devices for treating pediatric patients, in vitro diagnostic assays, digital therapeutics, devices for detecting and treating opioid-induced respiratory depression, and data science and cloud-based technologies. Proposed activities may include studies supporting an Investigational Device Exemption application, process development, non-clinical safety studies, clinical trials, and engagement with the FDA Center of Devices and Radiological Health. The goal is to successfully file an FDA premarket application for clearance/approval. The solicitation is open for applications and offers funding for Phase I, Phase II, and Fast Track projects. Phase I aims to establish the technical merit and feasibility of the proposed research, while Phase II continues the R&D efforts to advance the technology toward commercialization. Fast Track applications combine Phase I and Phase II into one application to reduce or eliminate the funding gap between phases. Small businesses that have received Phase I STTR awards are eligible to submit Phase II applications as "Renewal" applications.